Search academic texts

Information × Registration Number 0226U001881, (0124U003769) , R & D reports Title To determine the factors of long-term survival of patients with multiple myeloma in the conditions of modern therapy with the use of autologous transplantation of hematopoietic stem cells popup.stage_title Дослідити особливості пухлинного клону при плануванні програми лікування хворих на множинну мієлому, ефективності попереднього лікування з застосуванням ВДХТ з авто-ТГСК, вивчити показники гомеостазу в динаміці перебігу хвороби Head Novak Vasyl L., д.мед.н.Tsyapka Orest M., Кандидат медичних наук Registration Date 02-02-2026 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description1 To improve the long-term survival of patients with multiple myeloma in the conditions of modern therapy with the use of autologous transplantation of hematopoietic stem cells based on an individualized approach. popup.description2 The results of the study of the effectiveness of treatment with auto-HSCT in 87 patients with multiple myeloma (MM) aged 33 to 72 years, with an average age of 54.39±0.87 years, were presented. The effectiveness of tandem auto-HSCT was analyzed in 39 patients, and in 2 patients, repeated tandem auto-HSCT was performed in case of relapse 3 and 11 years after the first HSCT. The results of treatment were analyzed depending on gender, ISS stage of the disease, previous treatment, molecular cytogenetic prognostic risk factors, simple or tandem transplantation. CR and VGPR were achieved in 43.68% of patients with MM. In women, it was higher than in men (62.50% and 27.66%, respectively). Depending on the ISS stage, it was the lowest in stage 3. Less than a third of patients with relapsed MM achieved a response better than partial, and in patients with unfavorable cytogenetic factors it was even lower (27.25%). Different mobilization regimens have an impact on the collection of HSC and the effectiveness of treatment. The use of cyclophosphamide for mobilization is an effective method of collection, but the concentration of CD34+ cells in the blood is lower than with the use of etoposide or cytarabine. When planning tandem transplantations in patients with unfavorable cytogenetic factors or repeated procedures in patients of a younger age group, it is more appropriate to use high doses of etoposide or cytarabine, since the number of stem cells obtained is greater than after cyclophosphamide. Auto-HSCT significantly improves the life expectancy of patients with MM, the median survival was not reached in any of the evaluated subgroups. The better efficacy of tandem auto-HSCT was shown, as well as the dependence of survival on mobilization regimens, ISS disease stage, and cytogenetic prognostic factors. Better survival outcomes were found in primary patients than in relapses, which indicates the need for auto-HSCT in the first line of treatment. Product Description popup.authors Orest M. Tushnytskyi Knysh Nataliia V. Thir Hrystyna R. Savulak Galyna Romanivna Prymak Sofiia V. Orest Tsyapka Les Lukavetskyy popup.nrat_date 2026-02-02 Close